Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Drugs of Today

Volumn 49, Issue 12, 2013, Pages 761-768

  Larche, N E ^a   Mousa, S A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Chronic thromboembolic arterial hypertension; Pulmonary arterial hypertension; Riociguat; Targeted pathways

Indexed keywords

ENDOTHELIN; NITRIC OXIDE; PROSTACYCLIN; RIOCIGUAT;

ARTICLE; BLOOD PRESSURE; CELL PROLIFERATION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG VASOCONSTRICTION; PHASE 4 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION;

CHRONIC THROMBOEMBOLIC ARTERIAL HYPERTENSION; PULMONARY ARTERIAL HYPERTENSION; RIOCIGUAT; TARGETED PATHWAYS;

ANIMALS; CHRONIC DISEASE; DRUG APPROVAL; HUMANS; HYPERTENSION, PULMONARY; MOLECULAR TARGETED THERAPY; PULMONARY EMBOLISM; PYRAZOLES; PYRIMIDINES;

EID: 84892749033     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.12.2086995     Document Type: Article

References (41)

1. Simonneau, G., Robbins, I.M., Beghetti, M. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(1 Suppl): S43-54.
2. Humbert, M., Sitbon, O., Yaici, A. et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, 36(3): 549-55.
3. Seferian, A., Simonneau, G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev 2013, 22(129): 217-26.
4. Hoeper, M.M., Huscher, D., Ghofrani, H.A. et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Int J Cardiol 2013, 168(2): 871-80.
5. Germain, M., Eyries, M., Montani, D. et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet 2013, 45(5): 518-21.
6. Fedullo, P.F., Auger, W.R., Kerr, K.M., Rubin, L.J. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001, 345(20): 1465-72.
7. Mayer, E. Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2010, 19(115): 64-7.
8. Bonderman, D., Skoro-Sajer, N., Jakowitsch, J. et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007, 115(16): 2153-8.
9. Galie, N., Kim, N.H. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006, 3(7): 571-6.
10. Ghofrani, H.A., Galie, N., Grimminger, F. et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369(4): 330-40.
11. Ghofrani, H.A., D'Armini, A.M., Grimminger, F. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013, 369(4): 319-29.
12. Migneault, A., Sauvageau, S., Villeneuve, L., Thorin, E., Fournier, A., Leblanc, N., Dupuis, J. Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxide. Am J Respir Crit Care Med 2005, 171(5): 506-13.
13. Hocher, B., Schwarz, A., Fagan, K.A. et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000, 23(1): 19-26.
14. Dupuis, J., Hoeper, M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008, 31(2): 407-15.
15. Mubarak, K.K. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010, 104(1): 9-21.
16. Ghofrani, H.A., Wiedemann, R., Rose, F. et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002, 136(7): 515-22.
17. Simonneau, G., Barst, R.J., Galie, N. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165(6): 800-4.
18. de Jesus Perez, V.A., Rosenzweig, E., Rubin, L.J. et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012, 110(10): 1546-50.
19. Bhatia, S., Frantz, R.P., Severson, C.J., Durst, L.A., McGoon, M.D. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003, 78(10): 1207-13.
20. Straub, A., Stasch, J.P., Alonso-Alija, C., Benet-Buchholz, J., Ducke, B., Feurer, A., Furstner, C. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001, 11(6): 781-4.
21. Mittendorf, J., Weigand, S., Alonso-Alija, C. et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009, 4(5): 853-65.
22. Ko, F.N., Wu, C.C., Kuo, S.C., Lee, F.Y., Teng, C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84(12): 4226-33.
23. Schermuly, R.T., Stasch, J.P., Pullamsetti, S.S. et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008, 32(4): 881-91.
24. Geschka, S., Kretschmer, A., Sharkovska, Y. et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 2011, 6(7): e21853.
25. Lang, M., Kojonazarov, B., Tian, X. et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One 2012, 7(8): e43433.
26. Frey, R., Muck, W., Unger, S., Artmeier-Brandt, U., Weimann, G., Wensing, G. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008, 48(8): 926-34.
27. Effect of Riociguat on Bone Metabolism. http://clinicaltrials.gov/ct2/ show/NCT00855660?id=NCT00855660&rank=1. Accessed November 15, 2013.
28. Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID. http://clinicaltrials.gov/ct2/show/study/ NCT00680654?id=NCT00680654&rank=1. Accessed November 15, 2013.
29. Grimminger, F., Weimann, G., Frey, R. et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009, 33(4): 785-92.
30. Suntharalingam, J., Treacy, C.M., Doughty, N.J. et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008, 134(2): 229-36.
31. Jais, X., D'Armini, A.M., Jansa, P. et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008, 52(25): 2127-34.
32. Frey, R., Muck, W., Kirschbaum, N., Kratzschmar, J., Weimann, G., Wensing, G. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol 2011, 51(7): 1051-60.
33. Wilkens, H., Guth, A., Konig, J. et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104(11): 1218-22.
34. Stiebellehner, L., Petkov, V., Vonbank, K., Funk, G., Schenk, P., Ziesche, R., Block, L.H. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003, 123(4): 1293-5.
35. Ghofrani, H.A., Rose, F., Schermuly, R.T. et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003, 42(1): 158-64.
36. Hoeper, M.M., Faulenbach, C., Golpon, H., Winkler, J., Welte, T., Niedermeyer, J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004, 24(6): 1007-10.
37. Ikeda, D., Tsujino, I., Ohira, H. et al. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovasc Pharmacol 2005, 45(4): 286-9.
38. Hoeper, M.M., Markevych, I., Spiekerkoetter, E., Welte, T., Niedermeyer, J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005, 26(5): 858-63.
39. Halank, M., Kolditz, M., Opitz, C., Hoeffken, G., Ewert, R. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension. Wien Klin Wochenschr 2006, 118(1-2): 54-9.
40. Simonneau, G., Rubin, L.J., Galie, N. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149(8): 521-30.
41. Paul, G.A., Gibbs, J.S., Boobis, A.R., Abbas, A., Wilkins, M.R. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005, 60(1): 107-12.